Last reviewed 2026-05-17 · How we verify

High THC cannabis

Multidisciplinary Association for Psychedelic Studies · Phase 2 active Small molecule

High THC cannabis is a Small molecule drug developed by Multidisciplinary Association for Psychedelic Studies. It is currently in Phase 2 development. Also known as: Tetrahydrocannabinol.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	High THC cannabis
Also known as	Tetrahydrocannabinol
Sponsor	Multidisciplinary Association for Psychedelic Studies
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Cannabis Effects as a Function of Sex (PHASE1)
Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NA)
Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (PHASE1)
Pregnenolone as a Treatment for Cannabis Intoxication (PHASE2)
Behavioral Pharmacology of THC and Beta-Myrcene (PHASE1)
Tetrahydrocannabinol (THC) and Sleep (EARLY_PHASE1)
Cannabinoids as a Treatment for Insomnia in Major Depression (PHASE2)
Effect of Cannabis on Cigarette Use Behavior (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

High THC cannabis CI brief — competitive landscape report
High THC cannabis updates RSS · CI watch RSS
Multidisciplinary Association for Psychedelic Studies portfolio CI

Frequently asked questions about High THC cannabis

What is High THC cannabis?

High THC cannabis is a Small molecule drug developed by Multidisciplinary Association for Psychedelic Studies.

Who makes High THC cannabis?

High THC cannabis is developed by Multidisciplinary Association for Psychedelic Studies (see full Multidisciplinary Association for Psychedelic Studies pipeline at /company/multidisciplinary-association-for-psychedelic-studies).

Is High THC cannabis also known as anything else?

High THC cannabis is also known as Tetrahydrocannabinol.

What development phase is High THC cannabis in?

High THC cannabis is in Phase 2.

Manufacturer: Multidisciplinary Association for Psychedelic Studies — full pipeline
Also known as: Tetrahydrocannabinol

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing